Top Marijuana Stocks For February Watchlist
Are you looking for the best marijuana stocks to buy in February? Stocks of Canadian cannabis companies have considerably lost value as of 2022. Along with the rest of the market, the bulk of cannabis stocks fell to new lows in 2022. In general, new investors curious about the cannabis sector may want to start looking for businesses to invest in now. As the US continues to delay cannabis reform and banking, several renowned Canadian cannabis companies are trading at penny stock levels.
The White House issued a statement this week. Congress is spearheading the drive for cannabis banking and federal reform. The federal cannabis reform and SAFE Banking laws are now being delayed by Congress, which has had a negative effect on the cannabis industry. The truth is that the Senate has ignored marijuana legalization for a second year running.
Many cannabis investors have started short-term trading due to the best cannabis stocks to buy’s extreme volatility. To make money on marijuana stocks, active traders typically employ day trading and swing trading tactics. Despite possible recessions, there may be tremendous growth in the cannabis industry. Let’s look at 2 of the top marijuana stocks in Canada to watch now that they are cheaper.
[Read More] 2 Marijuana Stocks To Watch Today 2023
Best Canadian Cannabis Stocks To Watch In February 2023
- Tilray Brands, Inc. (NASDAQ: TLRY)
- Cronos Group Inc. (NASDAQ: CRON)
Tilray, Inc.
Tilray, Inc. is a cannabis consumer packaged goods (CPG) corporation with operations in Latin America, Europe, Australia, and North America. As a market leader in Canada, the company has earned a reputation as one of the most successful cannabis businesses worldwide. Tilray is preparing to enter the US market to expand its business. Tilray was the first business to grow and sell medical marijuana in Germany. The company claims that consumers in the US and Canadian markets are particularly interested in foods and beverages that include CBD. The goal of Tilray and Great North Distributors’ partnership in 2021 is to speed up the growth of Canada’s legal marijuana market.
Tilray reported second-quarter fiscal 2023 net revenue of $144.1 Million, On a constant currency basis, $157.6 million. Tilray also achieved $29.2 million operating cash flow and $25.4 million free cash flow. In addition, the company produced its 15th consecutive quarter of positive Adjusted EBITDA. Tilray Maintains a leading market share position in recreational cannabis in Canada and medical cannabis across Europe. Gross profit rose to $40.1 million, a 22% increase, year over year. Also, the Adjusted gross margin held at 29% compared to the year-ago quarter.
Words From The CEO
“During the second quarter, Tilray Brands took decisive, effective actions to manage operating cash flow and focus the business on accretive acquisitions and a path to long term profitability. And we have certainly done so – even amid an evolving retail environment – by removing costs and driving efficiencies across the platform in supply chain, procurement, packaging, and labor. We are close to achieving our increased annualized cost savings target of $130 million, consistent with our commitment to building a lean, efficient, and dynamic business that will realize tangible and immediate benefits as the market improves.”
Irwin D. Simon, Tilray Brands’ Chairman, and Chief Executive Officer
TLRY Stock Performance
On January 30th, the shares of TLRY closed at $3.08, up 14.50% in the past month of trading. The 52-week price range for the stock is $2.52-$9.08 and is up 14.50% year to date. According to CNN Business experts, TLRY stock has a 12-month consensus price objective of $3.30 per share. This represents a 7.32 percent increase over the previous trading price of $3.08.
[Read More] Best Marijuana Penny Stocks For Watchlist In February 2023
Cronos Group Inc.
With operations on five continents, Cronos Group Inc. is one of the biggest cannabis distributors in the world. Customers in Canada have only applauded the Cronos-owned cannabis businesses. Cronos also disclosed that a 10.5 percent stake in PharmaCann cost $110.4 million. The legalization of marijuana by the US government, among other factors, will impact the purchase. The agreement would also cover PharmaCann’s 23 dispensary locations and six production facilities. The company introduced a new line of cannabis candy earlier this year in two flavors. Adult clients undoubtedly enjoy these particular delicacies, according to a survey. In June, the company partnered with Geocann to employ the VESIsorb delivery technology for quicker absorption.
The third quarter of 2022 saw a $0.5 million increase in net revenue for Cronos, reaching $20.9 million. The third quarter of 2022 saw a $1.9 million increase in gross profit to $1.2 million. Rising cannabis flower sales in Israel, a diverse range of cannabis extract products with higher profit profiles than other product categories, and declining cannabis biomass prices were the primary factors in the improvement year over year. Additionally, Q3 2022’s Adjusted EBITDA increased by $25.1 million to $(21.7) million from Q3 2021. James Holm’s appointment as a chief financial officer was announced by Cronos. Bob Madore, who is departing the company, is replaced by Mr. Holm.
CRON Stock Performance
On January 30th, CRON stock closed at $2.44, with a 52-week price range of $2.39-$4.31. According to CNN Business analysts, CRON stock has a 12-month consensus forecast price target of $2.95 per share. This projection represents a 20.41% increase from the stock’s most recent trading price of $2.44.
[Read More] Best Marijuana Penny Stocks For Short-Term Trading List
Investing In Cannabis For 2023
Investors may profit in the near run in 2023, even though Canadian cannabis companies might not perform as well as their American rivals. Examining a company’s press releases and financial filings will help you choose the finest investments. In 2022, the cannabis market had high price volatility, which investors may have taken advantage of for quick gains. Remember that these are riskier assets and necessitate a more sophisticated trading approach. Congress may provide significant impetus for the cannabis business in 2023. It makes sense to monitor Canadian marijuana stocks as we begin the new year if you want to invest.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
